跳到正文
Brand AI

卫材

争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

返回词条共 3 条

  1. 2023

    勒索软件攻击和物流中断

    卫材在2023年6月经历了一次勒索软件攻击，导致一些物流系统关闭或中断。该事件是一次影响公司运营的网络安全和业务连续性事件。

    来源

  2. 2021

    卫材与Arena Pharmaceuticals因Belviq遭起诉

    提起诉讼

    2021年，一名原告及其已故妻子在新泽西联邦地区法院起诉卫材（Eisai）和Arena Pharmaceuticals，指称两家公司知道或理应知道Belviq可能存在致癌风险。诉状提出产品责任等主张。相关指控属于诉讼中的主张，报道未称法院已对此作出认定。

    一名原告及其已故妻子在新泽西联邦地区法院起诉Eisai和Arena Pharmaceuticals，指称两家公司知道或理应知道Belviq可能存在致癌风险。诉状提出产品责任等主张；报道未称法院已对此作出认定。

    来源摘录

    • Pharmaceutical company Eisai was sued alongside Arena Pharmaceuticals in the District of New Jersey on Monday by a plaintiff and his deceased wife, who alleged that the drug companies knew or should have known that Belviq, a prescription drug designed to be paired with diet and exercise to assist weight loss, could cause a risk of cancer.
    • Specific counts raised against the defendants include product liability, fraud, breach of warranty, violations of New Jersey state consumer protection law, and other claims.
    来源

  3. 2020

    卫材自愿撤回 Belviq

    宣布召回

    卫材表示，应美国食品药品监督管理局要求，自愿将 Belviq 和 Belviq XR 撤出美国市场；研究数据显示，服用 Belviq 的参与者癌症发生率较高。卫材表示不同意 FDA 对安全数据的解读。

    品牌回应

    • 召回 — Eisai

      Japan’s Eisai Inc., said it was voluntarily withdrawing the drug, Belviq.

    来源摘录

    • An extended-release version of the drug called Belviq XR also is being pulled from the market.
    • The maker of a weight loss drug pulled it from the market Thursday at the request of federal regulators, who said it posed an increased risk of cancer.
    • Japan’s Eisai Inc., said it was voluntarily withdrawing the drug, Belviq.
    来源